覆膜金属支架与胆管癌性狭窄患者胆囊炎及支架移位的关联
本回顾性队列研究纳入2008至2016年因恶性胆管狭窄行ERCP放置自膨式金属支架(SEMS)的645例患者,比较覆膜SEMS(CSEMS)与非覆膜SEMS(USEMS)的疗效与不良结局。两组临床成功率(93.0% vs 92.1%)及通畅时间(546.7 vs 557.9天)相似,但CSEMS组急性胆囊炎发生率更高(7.8% vs 1.2%),且多因素分析显示CSEMS与支架移位风险增加相关(HR 10.7)。
要点
- CSEMS与USEMS缓解恶性胆管梗阻的临床成功率及通畅时间相似。
- 胆囊完整者中,CSEMS组急性胆囊炎发生率高于USEMS组(7.8% vs 1.2%)。
- 多因素分析显示CSEMS使用与支架移位风险增加相关(HR 10.7)。
核心结论
- CSEMS与USEMS治疗恶性胆管狭窄的临床成功率和通畅时间相似,但CSEMS与支架移位及胆囊炎发生率增加相关。
- 作者认为USEMS疗效相当且安全性更优,这为其作为恶性胆管狭窄首选SEMS提供了有力论据。
研究设计与样本
- 回顾性队列研究,纳入2008至2016年因恶性胆管狭窄行ERCP并放置SEMS的全部连续患者,共645例。
- 比较CSEMS与USEMS的临床成功、通畅时间、支架功能障碍及不良结局,并行单因素和多因素分析识别支架功能障碍相关因素。
主要发现
- CSEMS组与USEMS组临床成功解除胆管梗阻率分别为93.0%与92.1%(P = .69)。
- CSEMS组与USEMS组通畅时间分别为546.7天与557.9天(P = .14)。
- 胆囊完整患者中,CSEMS组急性胆囊炎发生率为7.8%,USEMS组为1.2%(P < .001)。
- 多因素分析中,CSEMS使用与支架移位风险增加相关(HR 10.7,95%CI 4.1-27.7)。
临床怎么用
- 原文结论未据此给出推荐;作者认为USEMS疗效相当且安全性更优,这为其作为恶性胆管狭窄首选SEMS提供了有力论据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: ERCP with self-expandable metallic stent (SEMS) placement provides reliable and durable relief of malignant biliary obstruction. Our objective was to compare efficacy and adverse outcomes between uncovered SEMSs (USEMSs) and covered SEMSs (CSEMSs). METHODS: A retrospective cohort study was performed of all consecutive patients who underwent ERCP with SEMS placement for the management of a malignant bile duct stricture. Comparative analyses on clinical success, patency duration, stent dysfunction, and adverse outcomes were performed. Univariate and multivariable analyses were performed to identify factors associated with stent dysfunction. RESULTS: Six hundred forty-five patients underwent SEMS placement for the management of malignant bile duct stricture from 2008 to 2016. CSEMSs and USEMSs had similar rates of clinical success in relief of bile duct obstruction (93.0% vs 92.1%, respectively; P = .69) and patency duration (546.7 vs 557.9 days, P = .14). Among those with an intact gallbladder, the incidence of acute cholecystitis was higher in the CSEMS group compared with the USEMS group (7.8% vs 1.2%; P < .001). In the multivariable analysis, CSEMS use was associated with increased risk of stent migration (hazard ratio, 10.7; 95% confidence interval, 4.1-27.7). CONCLUSIONS: CSEMSs and USEMSs have similar clinical success rates and patency durations in management of malignant bile duct stricture. CSEMSs, however, are associated with increased rates of migration and cholecystitis. Comparable efficacy and superior safety profile of USEMSs render a compelling argument for its place as the preferred choice of SEMSs in the management of malignant biliary stricture.
引用
- Jang S, Stevens T, Parsi M, et al. Association of covered metallic stents with cholecystitis and stent migration in malignant biliary stricture. Gastrointest Endosc. 2017. PMID: 28867074. doi:10.1016/j.gie.2017.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。